Showing 7341-7350 of 7485 results for "".
- More Than 1,000 Ulthera Systems Sold Worldwidehttps://practicaldermatology.com/news/20120725-more_than_1000_ulthera_systems_sold_worldwide/2459764/Ulthera, Inc. has sold more than 1,000 Ulthera Systems globally, with more than 100,000 treatments performed using the System. Ultherapy is a non-invasive face and neck treatment to help lift and tighten. In the first half of 2012, the company rep
- Data Suggest Makucell's Asymmtate Reverses Gene Expression in Aging Skinhttps://practicaldermatology.com/news/20120725-makucell_announces_results_on_proprietary_technology_asymmtate/2459765/Makucell, Inc.'s Asymmtate(TM), the key ingredient in the Renewnt line, may reverse gene expression changes associated with aging skin and with lentigines. Findings for Asymmtate, a proprietary cosmetic ingredient that influences the gene co-act
- Galderma's Cetaphil Celebrates 65 Yearshttps://practicaldermatology.com/news/20120711-galdermas_cetaphil_celebarates_65_years/2459775/Galderma's Cetaphil Gentle Skin Cleanser is celebrating 65 years on the market. Introduced in 1947 as Cetaphil Cleansing Lotion, it was initially developed by a pharmacist for use as a compounding base. By the 1960s, the product was so popular t
- Cosmetic Bootcamp Adds Topics to Summer Meetinghttps://practicaldermatology.com/news/20120627-cosmetic_bootcamp_adds_topics_to_summer_meeting/2459778/The Cosmetic Bootcamp, an educational symposium for the core aesthetic specialties, has added topics to its summer sessions. These include Dr. David Sarwer (University of Pennsylvania, a nationally known expert on the psychology of cosmetic pati
- Makucell Unveils Renewnthttps://practicaldermatology.com/news/20120627-makucell_unveils_renewnt/2459779/Makucell, Inc., a pioneering regenerative biotechnology company, recently released the Renewnt (pronounced “Re-new-int”) brand. Renewnt's proprietary ingredient, Asymmtate, is a new approach to cellular aging, optimizing signals in the Wnt (pronounced “
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Free Podcasts on Complete UV Protectionhttps://practicaldermatology.com/news/20120612-free_podcasts_on_complete_uv_protection/2459785/On the new edition of "Healthy Vision with Dr. Val Jones," dermatologist and author Jeanine Downie, MD, and Stephen Cohen, OD, past president of the Arizona Optometric Association, join Dr. Val to talk about the importance of sun protection. Both doctors share tips on steps adults and children can t
- Merz Appoints New Vice President of Medical Dermatologyhttps://practicaldermatology.com/news/20120611-merz_appoints_new_vice_president_of_medical_dermatology/2459786/Merz, Inc. has appointed James P. Hartman as Vice President of Medical Dermatology. In the new role, Hartman will be responsible for the company's Medical and OTC/OTX dermatology business unit, which includes Naftin® (naftifine hydrochloride) and Mede
- EWG Releases 2012 Sunscreen Guide and Apphttps://practicaldermatology.com/news/20120608-ewg_releases_2012_sunscreen_guide_and_app/2459787/After rating 257 brands and more than 1,800 products, the Environmental Working Group (EWG) released its sixth annual Guide to Summer Sun. EWG recommends 1 in 4 of more than 800 beach and sport sunscreens, compared to 1 in 5 l
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with